Verily: Amy Abernethy
Verily has appointed Amy Abernethy as president of its clinical research business. Abernethy was most recently principal deputy commissioner of food and drugs and acting chief information officer at the US Food and Drug Administration. Prior to her role at FDA, Abernethy was chief medical officer, chief scientific officer, and senior vice president of Flatiron Health, now part of Roche. Abernethy has also been a professor of medicine at Duke University School of Medicine; director of the Center for Learning Health Care in the Duke Clinical Research Institute; and director of the Duke Cancer Care Research Program in the Duke Cancer Institute.
23andMe: Wade Walke
Wade Walke has joined 23andMe as VP of investor relations. Previously, he held the same title at Ionis Pharmaceuticals, and before that, he held various positions at Lexicon Pharmaceuticals, including associate director of bioinformatics in the department of functional genomics and head of communications and investor relations. Walke holds a BSc from Brigham Young University as well as PhD and MSc degrees from the University of Michigan.
Resolve Biosciences: Chris Barbazette
Resolve Biosciences has appointed Chris Barbazette as chief commercial officer. He will lead the firm's growing sales and marketing operations. Prior to this, he was senior VP of global sales and support at GenapSys. He has also held executive positions at Agendia and Affymetrix.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.